Targeting Sphingosine Kinases for the Treatment of Cancer

Clayton S. Lewis; Christina Voelkel-Johnson; Charles D. Smith

doi:10.1016/bs.acr.2018.04.015

Targeting Sphingosine Kinases for the Treatment of Cancer

Clayton S. Lewis
, Christina Voelkel-Johnson
, Charles D. Smith

Research output: Chapter in Book/Report/Conference proceeding › Chapter

39 Scopus citations

Abstract

Sphingosine kinases (SK1 and SK2) are key, druggable targets within the sphingolipid metabolism pathway that promote tumor growth and pathologic inflammation. A variety of isozyme-selective and dual inhibitors of SK1 and SK2 have been described in the literature, and at least one compound has reached clinical testing in cancer patients. In this chapter, we will review the rationale for targeting SKs and summarize the preclinical and emerging clinical data for ABC294640 as the first-in-class selective inhibitor of SK2.

Original language	English (US)
Title of host publication	Advances in Cancer Research
Editors	Charles E. Chalfant, Paul B. Fisher
Publisher	Academic Press Inc.
Pages	295-325
Number of pages	31
ISBN (Print)	9780128142233
DOIs	https://doi.org/10.1016/bs.acr.2018.04.015
State	Published - Jan 1 2018

Publication series

Name	Advances in Cancer Research
Volume	140
ISSN (Print)	0065-230X
ISSN (Electronic)	2162-5557

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

Access to Document

10.1016/bs.acr.2018.04.015

Cite this

@inbook{a7d6d783223941c6bbe27673db8142e3,

title = "Targeting Sphingosine Kinases for the Treatment of Cancer",

abstract = "Sphingosine kinases (SK1 and SK2) are key, druggable targets within the sphingolipid metabolism pathway that promote tumor growth and pathologic inflammation. A variety of isozyme-selective and dual inhibitors of SK1 and SK2 have been described in the literature, and at least one compound has reached clinical testing in cancer patients. In this chapter, we will review the rationale for targeting SKs and summarize the preclinical and emerging clinical data for ABC294640 as the first-in-class selective inhibitor of SK2.",

author = "Lewis, \{Clayton S.\} and Christina Voelkel-Johnson and Smith, \{Charles D.\}",

note = "Publisher Copyright: {\textcopyright} 2018 Elsevier Inc.",

year = "2018",

month = jan,

day = "1",

doi = "10.1016/bs.acr.2018.04.015",

language = "English (US)",

isbn = "9780128142233",

series = "Advances in Cancer Research",

publisher = "Academic Press Inc.",

pages = "295--325",

editor = "Chalfant, \{Charles E.\} and Fisher, \{Paul B.\}",

booktitle = "Advances in Cancer Research",

address = "United States",

}

TY - CHAP

T1 - Targeting Sphingosine Kinases for the Treatment of Cancer

AU - Lewis, Clayton S.

AU - Voelkel-Johnson, Christina

AU - Smith, Charles D.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Sphingosine kinases (SK1 and SK2) are key, druggable targets within the sphingolipid metabolism pathway that promote tumor growth and pathologic inflammation. A variety of isozyme-selective and dual inhibitors of SK1 and SK2 have been described in the literature, and at least one compound has reached clinical testing in cancer patients. In this chapter, we will review the rationale for targeting SKs and summarize the preclinical and emerging clinical data for ABC294640 as the first-in-class selective inhibitor of SK2.

AB - Sphingosine kinases (SK1 and SK2) are key, druggable targets within the sphingolipid metabolism pathway that promote tumor growth and pathologic inflammation. A variety of isozyme-selective and dual inhibitors of SK1 and SK2 have been described in the literature, and at least one compound has reached clinical testing in cancer patients. In this chapter, we will review the rationale for targeting SKs and summarize the preclinical and emerging clinical data for ABC294640 as the first-in-class selective inhibitor of SK2.

UR - https://www.scopus.com/pages/publications/85048492365

UR - https://www.scopus.com/pages/publications/85048492365#tab=citedBy

U2 - 10.1016/bs.acr.2018.04.015

DO - 10.1016/bs.acr.2018.04.015

M3 - Chapter

C2 - 30060814

AN - SCOPUS:85048492365

SN - 9780128142233

T3 - Advances in Cancer Research

SP - 295

EP - 325

BT - Advances in Cancer Research

A2 - Chalfant, Charles E.

A2 - Fisher, Paul B.

PB - Academic Press Inc.

ER -

Targeting Sphingosine Kinases for the Treatment of Cancer

Abstract

Publication series

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this